Pivotal bioVenture Partners Research
Investment Thesis
Pivotal bioVenture Partners is the venture capital arm of Pivotal Life Sciences, a global healthcare investment firm that supports companies developing high-impact therapeutics for major unmet medical needs. The firm was established in 2017 and invests in transformative, therapeutic-focused healthcare companies across North America and Europe. Its stated approach is to provide financing and guidance at all stages of a company's evolution, from company creation through clinical development and commercialization. The broader Pivotal platform also supplies academic translational opportunities for company creation, expands portfolio company pipelines, generates deal flow and widens the base of syndication partners.
Stage Focus
The firm describes itself as a full-lifecycle investor. The 2017 launch coverage positioned the first fund around preclinical and early-stage biotechs, and the firm does company building and seed formation. The news record shows it also follows into large later rounds and public offerings: Series C and D financings (Zenas, Obsidian, Evommune, MapLight, Avalyn) and IPO-stage companies. Stage preferences are therefore stated broadly rather than as a narrow band.
Check Size
The firm does not publish a check size range. Fund I was over $300M and Fund II closed at $389M in December 2023, bringing total bioVenture commitments to $689M. Per press coverage at the Fund II close, more than 75% of Fund II was still available to deploy, which implies the firm can write both small initial checks and large follow-ons. No check size range is asserted here.
Lead Tendency
The site does not say whether the firm leads. Partners hold board seats and observer seats across the portfolio (Rob Hopfner on Evommune, Plexium, Rallybio and LAND Therapeutics; Jeni Lee on Addition Therapeutics and DermBiont; Peter Bisgaard on MapLight, Engrail and Addition), which points to an active, engaged investor, but lead versus follow is recorded as unknown.
Recent Activity
- Fund II ($389M) closed in December 2023; the firm describes it as backing North American and European companies.
- December 2025: portfolio companies MapLight Therapeutics and Evommune completed IPOs.
- August 2025: Sanofi completed its acquisition of Vigil Neuroscience.
- July 2025: MapLight raised a $372.5M Series D and Avalyn raised a $100M Series D.
- July 2025: BioMarin completed its acquisition of Inozyme.
- April 2025: Novartis completed its acquisition of Anthos Therapeutics (up to $3.1B, $925M upfront).
- Portfolio page additions in 2026 include Mosanna Therapeutics and Parabilis Medicines, and the firm's own page also lists Cybin, Immunome and LB Pharmaceuticals added in late 2025.
Portfolio Highlights
The portfolio page lists 39 companies. Exits include Karuna Therapeutics (acquired by BMS), Gracell (AstraZeneca), Fusion Pharmaceuticals (AstraZeneca), Anthos (Novartis), Inozyme (BioMarin), Vigil Neuroscience (Sanofi), Exscientia (merged with Recursion), Akouos, Alkahest (Grifols) and Omniome (PacBio). Public companies include Vaxcyte, Arcutis, Oculis, Trevi, Rallybio, Zenas, BioAge, MapLight, Evommune and LB Pharmaceuticals. Therapeutic areas are heavily neuroscience, immunology and inflammation, oncology, dermatology, respiratory and rare disease, with some tools and diagnostics companies (GRAIL, Twist Bioscience, Omniome).
Team
- Peter Bisgaard, Managing Partner (US): joined 2017, formerly Senior Partner at Novo Holdings / Novo Ventures (US); earlier McKinsey. San Francisco.
- Rob Hopfner, Managing Partner (US): joined 2017, formerly Managing Director at Bay City Capital; RPh, PhD pharmacology, MBA. Boards include Evommune, Plexium, Rallybio and LAND Therapeutics. San Francisco.
- Tony Ho, Senior Science Partner: former EVP and Head of R&D at CRISPR Therapeutics, SVP at AstraZeneca, head of neurology and ophthalmology at Merck. Boston.
- Glenn Batchelder, Venture Partner: former CEO of Civitas, BIND and Acceleron. Boston.
- Jeni Lee, Partner: joined 2019, formerly Novo Ventures; early-stage therapeutics focus. San Francisco.
- Brian Mills, Vice President: joined 2022 from Jefferies biotech research. San Francisco.
- AJ Velasquez-Mao, Senior Associate: joined 2026 from Dolby Family Ventures. San Francisco.
Decision Process
The firm is run by a partnership of managing partners with scientific and operating partners attached. The site does not describe a formal committee or timeline, so the decision process is recorded as partnership and the timeline as unknown.
Founder Preferences
The team is scientific and operator-heavy: clinicians, pharmacologists, former biotech CEOs and R&D heads. This suggests a preference for scientifically differentiated therapeutic founders and company-creation situations, including academic translational spinouts, where the partners can help build the company. Founders running asset-centric clinical-stage therapeutic companies fit the pattern; non-therapeutic digital health does not.
Geographic Focus
North America and Europe for the bioVenture Partners fund, with offices in San Francisco (headquarters) and Boston. Pivotal bioVenture Partners China, a separate vehicle with offices in Shanghai and Hong Kong, covers Greater China. The Public Equity arm invests in listed life sciences companies.
Gaps
Check size, AUM, lead tendency and fund vintage deployment pace are not disclosed on the site. Stage dates on portfolio entries are not published and are left blank rather than inferred.